Asterias Biotherapeutics (AST) Sees Strong Trading Volume
Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) saw an uptick in trading volume on Tuesday . 1,341,034 shares were traded during mid-day trading, an increase of 639% from the previous session’s volume of 181,365 shares.The stock last traded at $0.98 and had previously closed at $0.72.
Several brokerages recently issued reports on AST. Zacks Investment Research cut Asterias Biotherapeutics from a “buy” rating to a “hold” rating in a report on Tuesday. HC Wainwright set a $11.00 price objective on Asterias Biotherapeutics and gave the stock a “buy” rating in a report on Tuesday, October 9th.
Asterias Biotherapeutics (NYSEAMERICAN:AST) last released its earnings results on Friday, November 9th. The biotechnology company reported ($0.08) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.10) by $0.02. The business had revenue of $0.12 million during the quarter, compared to analyst estimates of $0.11 million.
Asterias Biotherapeutics Company Profile (NYSEAMERICAN:AST)
Asterias Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. Its clinical stage programs include AST-OPC1, an oligodendrocyte progenitor cell population derived from pluripotent stem cells that is in Phase I/IIa clinical trial for spinal cord injuries; AST-VAC2 is a non-patient-specific cancer immunotherapy derived from pluripotent stem cells for the treatment of non-small cell lung cancer; and AST-VAC1, a patient-specific cancer immunotherapy that has completed Phase II clinical trial for the treatment of acute myeloid leukemia.
Featured Story: Investing in Growth Stocks
Receive News & Ratings for Asterias Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.